The Medicines Company (MDCO) 29.79 $MDCO
Technical Notes Covering Pharma Equities -- Valeant Pharma Intl., Salix Pharma, Medicines, Hospira, and Horizon Pharma
PR Newswire - Fri Feb 13, 7:45AM CST
Editor Note: For more information about this release, please scroll to bottom.
VRX: 167.00 (-0.50), MDCO: 29.79 (+0.91), HZNP: 16.84 (-0.41), SLXP: 152.35 (+3.17), HSP: 87.35 (unch), VRX.TO: 207.95 (-1.47)
Alnylam Reports Narrower Loss in Q4, Focuses on Pipeline - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Feb 13, 7:19AM CST
Alnylam's (ALNY) fourth-quarter 2014 loss of 28 cents per share was much narrower than the Zacks Consensus Estimate of a loss of 66 cents and the year-ago loss of 51 cents per share.
MON: 124.77 (+2.00), ALNY: 95.54 (+1.67), MDCO: 29.79 (+0.91), OPHT: 51.11 (+0.12)
Tetraphase Fights Drug-Resistant Bugs As M&A Heats Up
at Investor's Business Daily - Mon Feb 09, 3:53PM CST
One lesson to draw from recent M&A in the pharma space: Superbug drugs are hot. Last year, Actavis (ACT) plunked down $675 million for Durata Therapeutics, whose drug Dalvance fights some of the nastiest specimens of the class known as gram-positive...
TTPH: 35.18 (-0.73), ACT: 285.37 (+3.71), MDCO: 29.79 (+0.91), AZN: 69.96 (+0.20), MRK: 58.81 (-0.07)
The Medicines Company to participate in Leerink Global Healthcare Conference
Business Wire - Thu Feb 05, 6:01AM CST
The Medicines Company (NASDAQ:MDCO) is scheduled to present at the Leerink Global Healthcare Conference in New York, NY on Thursday, February 12th, 2015 at 8:05 AM EST.
MDCO: 29.79 (+0.91)
The Medicines Company completes Annovation Biopharma's acquisition
M2 - Thu Feb 05, 5:53AM CST
Healthcare company The Medicines Company (Nasdaq:MDCO) announced on Wednesday the completion of its acquisition of all of the outstanding equity of Annovation Biopharma Inc, a company focused on creating more effective, safer therapies for anaesthesia and critical care.
MDCO: 29.79 (+0.91)
The Medicines Company reports February 18
Seeking Alpha - at Seeking Alpha - Wed Feb 04, 8:00AM CST
MDCO: 29.79 (+0.91)
The Medicines Company Acquires Annovation Biopharma, Inc.
Business Wire - Wed Feb 04, 6:01AM CST
The Medicines Company (NASDAQ: MDCO) today announced that it has completed its acquisition of all of the outstanding equity of Annovation Biopharma, Inc., a company focused on creating more effective, safer therapies for anesthesia and critical care. Based on technology licensed from Massachusetts General Hospital, Annovation is developing ABP-700, a novel intravenous anesthetic which in Phase 1 clinical studies has demonstrated potent and rapidly reversible anesthetic effects.
MDCO: 29.79 (+0.91)
The Medicines Company to Announce Fourth Quarter and Full Year 2014 Financial Results on Wednesday, February 18, 2015
Business Wire - Wed Feb 04, 5:30AM CST
The Medicines Company (NASDAQ:MDCO) has scheduled its quarterly conference call for Wednesday, February 18th at 8:30 a.m. Eastern Time to discuss fourth quarter and full year 2014 financial results, operational developments, and outlook for 2015.
MDCO: 29.79 (+0.91)
Product and Pipeline Analysis of the Antibacterial Drugs Market 2015
M2 - Sat Jan 31, 12:53AM CST
Research and Markets (http://www.researchandmarkets.com/research/knzdss/a_product_and) has announced the addition of the "A Product and Pipeline Analysis of the Antibacterial Drugs Market " report to their offering. Drug-resistant bacteria, or superbugs, pose a serious threat to human health. Developing new antibacterial drugs requires a great deal of time, effort, expenditure, and scientific research, making it a less-attractive segment for investment by pharmaceutical companies. This research service focuses on the global antibacterial drugs (antibiotics) market, with particular focus on the antibiotics currently under development. A list of currently available and marketed antibacterial drugs under the approved antibacterial drug classes has been provided. Product and pipeline assessment for recently approved antibacterial drugs, antibacterials under FDA review, as well as phase 3 antibacterial drug candidates have been provided. A detailed overview of the various regulatory approaches to foster innovation in the development of new antibiotics has been provided as well. Antibacterial Drugs Listed - Tedizolid Phosphate-Cubist Pharmaceuticals - Dalbavancin (Dalvance)-Durata Therapeutics - Ceftolozane Tazobactam-Cubist Pharmaceuticals - Oritavancin (Orbactiv)-The Medicines Company - Ceftazidime Avibactam (CAZ-AVI)-AstraZeneca - Cadazolid-Actelion Pharmaceuticals - Carbavance-Rempex Pharmaceuticals (The Medicines Company) - Delafloxacin-Melinta Therapeutics - Eravacycline-Tetraphase Pharmaceuticals - Plazomicin-Achaogen - Solithromycin-Cempra Pharmaceuticals - Surotomycin-Cubist Pharmaceuticals Key Topics Covered: 1. Executive Summary 2. Introduction 3. Classification Of Antibacterial Drugs By Mechanism Of Action 4. Antibacterial Drugs Market-Pipeline Analysis 5. Antibacterial Drugs Market-Major Clinical Milestones 6. Antibacterial Drugs Market-Product Dashboard Of Recently Approved And Late-Stage Pipeline Drug Candidates 7. Antibiotic Resistance-A Critical Unmet Need That Poses Challenges To Antibiotic R&D 8. Antibacterial Drugs Market-Timeline Of Key Events 9. Regulatory Approaches To Stimulate Antibiotics R&D 10. Antibacterial Drugs Market-Key Companies To Watch 11. Conclusions 12. Appendix Companies Mentioned - Achaogen - Actelion Pharmaceuticals - AstraZeneca - Cempra Pharmaceuticals - Cubist Pharmaceuticals - Durata Therapeutics - Melinta Therapeutics - Rempex Pharmaceuticals - Tetraphase Pharmaceuticals - The Medicines Company For more information visit http://www.researchandmarkets.com/research/kn...roduct_and
DRTX: 24.16 (+0.41), TTPH: 35.18 (-0.73), CBSTZ: 0.06 (unch), MDCO: 29.79 (+0.91)
Defense Stocks Are Fabulous - Cramer's Lightning Round (1/29/15)
SA Editor Mohit Manghnani - Seeking Alpha - Fri Jan 30, 4:30AM CST
Stocks discussed on the Lightning Round segment of Jim Cramer's Mad Money Program, Thursday, January 29. Bullish Calls: Trimble Navigation (NASDAQ: TRMB ): "I do prefer Garmin (NASDAQ: GRMN ) if you want to be in that game." KKR...
LMT: 196.95 (-0.53), BX: 37.40 (+0.49), TRMB: 26.86 (-0.40), MDCO: 29.79 (+0.91), NOC: 167.14 (-0.15), GRMN: 55.93 (+0.02), JDSU: 13.26 (+0.23), PPC: 26.75 (+0.77), TSN: 40.70 (-0.09), KKR: 24.42 (+0.06), ATK: 140.03 (+0.78), MTW: 21.86 (+0.34), ARRY: 8.05 (+0.08)
The Medicines Company: Raplixa Approval Is Likely, Manufacturing Risk Is Low
Beacon VP Investments - at Seeking Alpha - Thu Jan 29, 3:13PM CST
MDCO: 29.79 (+0.91)
PDUFA date approaches for Fibrocaps BLA
Seeking Alpha - at Seeking Alpha - Wed Jan 28, 12:29PM CST
MDCO: 29.79 (+0.91)
The Medicines Co. Gets CHMP Recommendation for 3 Drugs - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Jan 27, 5:30PM CST
The Medicines Company (MDCO) announced that the CHMP has issued positive opinions regarding the marketing authorization for Orbactiv, Raplixa and Kengrexal.
MDCO: 29.79 (+0.91), ALXN: 182.29 (+6.02), RGDO: 1.17 (+0.02), CELG: 115.88 (+0.16)
European Ad Comm recommends approval of three Medicines Company products
Seeking Alpha - at Seeking Alpha - Fri Jan 23, 7:07AM CST
MDCO: 29.79 (+0.91)
The Medicines Company Receives CHMP Positive Opinions for Three Hospital Acute Care Products: KENGREXAL(TM) (cangrelor), ORBACTIV(TM) (oritavancin) and RAPLIXA(TM) (sealant powder)
Business Wire - Fri Jan 23, 6:15AM CST
The Medicines Company today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) issued positive opinions recommending marketing authorization for three of its pipeline development candidates - KENGREXAL(TM) (cangrelor), ORBACTIV(TM) (oritavancin), and RAPLIXA(TM) (sealant powder). These positive opinion recommendations represent category firsts across three therapeutic areas:
MDCO: 29.79 (+0.91)
Eyes On Medicines Company (MDCO): Highlighted Storm The Castle Stock
at The Street - Wed Jan 21, 11:40AM CST
Trade-Ideas LLC identified Medicines Company (MDCO) as a "storm the castle" (crossing above the 200-day simple moving average on higher than normal relative volume) candidate
MDCO: 29.79 (+0.91)
Upgrade Alert for Medicines Co (MDCO)
Comtex SmarTrend(R) - Wed Jan 21, 8:11AM CST
Medicines Co (NASDAQ:MDCO) was upgraded from Market Perform to Outperform at Leerink today. The stock closed yesterday at $24.70 on volume of 1.2 million shares, below average daily volume of 1.2 million. In the past 52 weeks, Medicines Co share prices have been bracketed by a low of $12.33 and a high of $41.28 and closed yesterday at $24.70, 100% above that low price. Over the past week, the 200-day moving average (MA) has remained constant while the 50-day MA has remained constant.
MDCO: 29.79 (+0.91)
The FDA Should Approve The New Hemostatic Product From The Medicines Company
Clinically Sound Investor - at Seeking Alpha - Sat Jan 17, 10:54AM CST
MDCO: 29.79 (+0.91)
Technical Coverage on Pharma Stocks - Hospira, Auxilium Pharma, Medicines, SciClone Pharma, and Nektar Therapeutics
PR Newswire - Tue Jan 13, 7:30AM CST
Investor-Edge has initiated coverage on the following equities: Hospira Inc. (NYSE: HSP), Auxilium Pharmaceuticals Inc. (NASDAQ: AUXL), The Medicines Company (NASDAQ: MDCO), SciClone Pharmaceuticals Inc. (NASDAQ: SCLN), and Nektar Therapeutics (NASDAQ: NKTR). Free research on these five companies can be accessed at: http://investor-edge.com/register. On Monday, January 12, 2015, the NASDAQ Composite ended at 4,664.71, down 0.84%, the Dow Jones Industrial Average declined 0.54%, to finish the day at 17,640.84, and the S&P 500 closed at 2,028.26, down 0.81%. The losses were broad based as nine out of ten sectors ended the session in negative. The S&P 500 Health Care Sector Index ended the day at 812.68, down 0.07%, while the index has advanced 11.54% in the previous three months. Register for your complimentary reports on these five stocks at:
MDCO: 29.79 (+0.91), AUXL: 36.47 (-0.06), SCLN: 7.85 (+0.08), NKTR: 13.54 (-0.14), HSP: 87.35 (unch)
FDA clears Daiichi-Sankyo anticoagulant
Seeking Alpha - at Seeking Alpha - Thu Jan 08, 6:55PM CST
PTLA: 34.96 (+3.13), PFE: 34.64 (-0.23), BMY: 60.04 (+0.56), JNJ: 99.62 (+1.18), ISIS: 63.86 (-0.43), MDCO: 29.79 (+0.91), BAX: 70.39 (+0.31), AZN: 69.96 (+0.20), MRK: 58.81 (-0.07), SCLN: 7.85 (+0.08), MSLI: 1.96 (+0.08)
Technical Notes Covering Pharma Equities -- Valeant Pharma Intl., Salix Pharma, Medicines, Hospira, and Horizon Pharma
PR Newswire - Fri Feb 13, 7:45AM CST
Editor Note: For more information about this release, please scroll to bottom.
VRX: 167.00 (-0.50), MDCO: 29.79 (+0.91), HZNP: 16.84 (-0.41), SLXP: 152.35 (+3.17), HSP: 87.35 (unch), VRX.TO: 207.95 (-1.47)
Alnylam Reports Narrower Loss in Q4, Focuses on Pipeline - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Feb 13, 7:19AM CST
Alnylam's (ALNY) fourth-quarter 2014 loss of 28 cents per share was much narrower than the Zacks Consensus Estimate of a loss of 66 cents and the year-ago loss of 51 cents per share.
MON: 124.77 (+2.00), ALNY: 95.54 (+1.67), MDCO: 29.79 (+0.91), OPHT: 51.11 (+0.12)
Tetraphase Fights Drug-Resistant Bugs As M&A Heats Up
at Investor's Business Daily - Mon Feb 09, 3:53PM CST
One lesson to draw from recent M&A in the pharma space: Superbug drugs are hot. Last year, Actavis (ACT) plunked down $675 million for Durata Therapeutics, whose drug Dalvance fights some of the nastiest specimens of the class known as gram-positive...
TTPH: 35.18 (-0.73), ACT: 285.37 (+3.71), MDCO: 29.79 (+0.91), AZN: 69.96 (+0.20), MRK: 58.81 (-0.07)
The Medicines Company to participate in Leerink Global Healthcare Conference
Business Wire - Thu Feb 05, 6:01AM CST
The Medicines Company (NASDAQ:MDCO) is scheduled to present at the Leerink Global Healthcare Conference in New York, NY on Thursday, February 12th, 2015 at 8:05 AM EST.
MDCO: 29.79 (+0.91)
The Medicines Company completes Annovation Biopharma's acquisition
M2 - Thu Feb 05, 5:53AM CST
Healthcare company The Medicines Company (Nasdaq:MDCO) announced on Wednesday the completion of its acquisition of all of the outstanding equity of Annovation Biopharma Inc, a company focused on creating more effective, safer therapies for anaesthesia and critical care.
MDCO: 29.79 (+0.91)
The Medicines Company reports February 18
Seeking Alpha - at Seeking Alpha - Wed Feb 04, 8:00AM CST
MDCO: 29.79 (+0.91)
The Medicines Company Acquires Annovation Biopharma, Inc.
Business Wire - Wed Feb 04, 6:01AM CST
The Medicines Company (NASDAQ: MDCO) today announced that it has completed its acquisition of all of the outstanding equity of Annovation Biopharma, Inc., a company focused on creating more effective, safer therapies for anesthesia and critical care. Based on technology licensed from Massachusetts General Hospital, Annovation is developing ABP-700, a novel intravenous anesthetic which in Phase 1 clinical studies has demonstrated potent and rapidly reversible anesthetic effects.
MDCO: 29.79 (+0.91)
The Medicines Company to Announce Fourth Quarter and Full Year 2014 Financial Results on Wednesday, February 18, 2015
Business Wire - Wed Feb 04, 5:30AM CST
The Medicines Company (NASDAQ:MDCO) has scheduled its quarterly conference call for Wednesday, February 18th at 8:30 a.m. Eastern Time to discuss fourth quarter and full year 2014 financial results, operational developments, and outlook for 2015.
MDCO: 29.79 (+0.91)
Product and Pipeline Analysis of the Antibacterial Drugs Market 2015
M2 - Sat Jan 31, 12:53AM CST
Research and Markets (http://www.researchandmarkets.com/research/knzdss/a_product_and) has announced the addition of the "A Product and Pipeline Analysis of the Antibacterial Drugs Market " report to their offering. Drug-resistant bacteria, or superbugs, pose a serious threat to human health. Developing new antibacterial drugs requires a great deal of time, effort, expenditure, and scientific research, making it a less-attractive segment for investment by pharmaceutical companies. This research service focuses on the global antibacterial drugs (antibiotics) market, with particular focus on the antibiotics currently under development. A list of currently available and marketed antibacterial drugs under the approved antibacterial drug classes has been provided. Product and pipeline assessment for recently approved antibacterial drugs, antibacterials under FDA review, as well as phase 3 antibacterial drug candidates have been provided. A detailed overview of the various regulatory approaches to foster innovation in the development of new antibiotics has been provided as well. Antibacterial Drugs Listed - Tedizolid Phosphate-Cubist Pharmaceuticals - Dalbavancin (Dalvance)-Durata Therapeutics - Ceftolozane Tazobactam-Cubist Pharmaceuticals - Oritavancin (Orbactiv)-The Medicines Company - Ceftazidime Avibactam (CAZ-AVI)-AstraZeneca - Cadazolid-Actelion Pharmaceuticals - Carbavance-Rempex Pharmaceuticals (The Medicines Company) - Delafloxacin-Melinta Therapeutics - Eravacycline-Tetraphase Pharmaceuticals - Plazomicin-Achaogen - Solithromycin-Cempra Pharmaceuticals - Surotomycin-Cubist Pharmaceuticals Key Topics Covered: 1. Executive Summary 2. Introduction 3. Classification Of Antibacterial Drugs By Mechanism Of Action 4. Antibacterial Drugs Market-Pipeline Analysis 5. Antibacterial Drugs Market-Major Clinical Milestones 6. Antibacterial Drugs Market-Product Dashboard Of Recently Approved And Late-Stage Pipeline Drug Candidates 7. Antibiotic Resistance-A Critical Unmet Need That Poses Challenges To Antibiotic R&D 8. Antibacterial Drugs Market-Timeline Of Key Events 9. Regulatory Approaches To Stimulate Antibiotics R&D 10. Antibacterial Drugs Market-Key Companies To Watch 11. Conclusions 12. Appendix Companies Mentioned - Achaogen - Actelion Pharmaceuticals - AstraZeneca - Cempra Pharmaceuticals - Cubist Pharmaceuticals - Durata Therapeutics - Melinta Therapeutics - Rempex Pharmaceuticals - Tetraphase Pharmaceuticals - The Medicines Company For more information visit http://www.researchandmarkets.com/research/kn...roduct_and
DRTX: 24.16 (+0.41), TTPH: 35.18 (-0.73), CBSTZ: 0.06 (unch), MDCO: 29.79 (+0.91)
Defense Stocks Are Fabulous - Cramer's Lightning Round (1/29/15)
SA Editor Mohit Manghnani - Seeking Alpha - Fri Jan 30, 4:30AM CST
Stocks discussed on the Lightning Round segment of Jim Cramer's Mad Money Program, Thursday, January 29. Bullish Calls: Trimble Navigation (NASDAQ: TRMB ): "I do prefer Garmin (NASDAQ: GRMN ) if you want to be in that game." KKR...
LMT: 196.95 (-0.53), BX: 37.40 (+0.49), TRMB: 26.86 (-0.40), MDCO: 29.79 (+0.91), NOC: 167.14 (-0.15), GRMN: 55.93 (+0.02), JDSU: 13.26 (+0.23), PPC: 26.75 (+0.77), TSN: 40.70 (-0.09), KKR: 24.42 (+0.06), ATK: 140.03 (+0.78), MTW: 21.86 (+0.34), ARRY: 8.05 (+0.08)
The Medicines Company: Raplixa Approval Is Likely, Manufacturing Risk Is Low
Beacon VP Investments - at Seeking Alpha - Thu Jan 29, 3:13PM CST
MDCO: 29.79 (+0.91)
PDUFA date approaches for Fibrocaps BLA
Seeking Alpha - at Seeking Alpha - Wed Jan 28, 12:29PM CST
MDCO: 29.79 (+0.91)
The Medicines Co. Gets CHMP Recommendation for 3 Drugs - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Jan 27, 5:30PM CST
The Medicines Company (MDCO) announced that the CHMP has issued positive opinions regarding the marketing authorization for Orbactiv, Raplixa and Kengrexal.
MDCO: 29.79 (+0.91), ALXN: 182.29 (+6.02), RGDO: 1.17 (+0.02), CELG: 115.88 (+0.16)
European Ad Comm recommends approval of three Medicines Company products
Seeking Alpha - at Seeking Alpha - Fri Jan 23, 7:07AM CST
MDCO: 29.79 (+0.91)
The Medicines Company Receives CHMP Positive Opinions for Three Hospital Acute Care Products: KENGREXAL(TM) (cangrelor), ORBACTIV(TM) (oritavancin) and RAPLIXA(TM) (sealant powder)
Business Wire - Fri Jan 23, 6:15AM CST
The Medicines Company today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) issued positive opinions recommending marketing authorization for three of its pipeline development candidates - KENGREXAL(TM) (cangrelor), ORBACTIV(TM) (oritavancin), and RAPLIXA(TM) (sealant powder). These positive opinion recommendations represent category firsts across three therapeutic areas:
MDCO: 29.79 (+0.91)
Eyes On Medicines Company (MDCO): Highlighted Storm The Castle Stock
at The Street - Wed Jan 21, 11:40AM CST
Trade-Ideas LLC identified Medicines Company (MDCO) as a "storm the castle" (crossing above the 200-day simple moving average on higher than normal relative volume) candidate
MDCO: 29.79 (+0.91)
Upgrade Alert for Medicines Co (MDCO)
Comtex SmarTrend(R) - Wed Jan 21, 8:11AM CST
Medicines Co (NASDAQ:MDCO) was upgraded from Market Perform to Outperform at Leerink today. The stock closed yesterday at $24.70 on volume of 1.2 million shares, below average daily volume of 1.2 million. In the past 52 weeks, Medicines Co share prices have been bracketed by a low of $12.33 and a high of $41.28 and closed yesterday at $24.70, 100% above that low price. Over the past week, the 200-day moving average (MA) has remained constant while the 50-day MA has remained constant.
MDCO: 29.79 (+0.91)
The FDA Should Approve The New Hemostatic Product From The Medicines Company
Clinically Sound Investor - at Seeking Alpha - Sat Jan 17, 10:54AM CST
MDCO: 29.79 (+0.91)
Technical Coverage on Pharma Stocks - Hospira, Auxilium Pharma, Medicines, SciClone Pharma, and Nektar Therapeutics
PR Newswire - Tue Jan 13, 7:30AM CST
Investor-Edge has initiated coverage on the following equities: Hospira Inc. (NYSE: HSP), Auxilium Pharmaceuticals Inc. (NASDAQ: AUXL), The Medicines Company (NASDAQ: MDCO), SciClone Pharmaceuticals Inc. (NASDAQ: SCLN), and Nektar Therapeutics (NASDAQ: NKTR). Free research on these five companies can be accessed at: http://investor-edge.com/register. On Monday, January 12, 2015, the NASDAQ Composite ended at 4,664.71, down 0.84%, the Dow Jones Industrial Average declined 0.54%, to finish the day at 17,640.84, and the S&P 500 closed at 2,028.26, down 0.81%. The losses were broad based as nine out of ten sectors ended the session in negative. The S&P 500 Health Care Sector Index ended the day at 812.68, down 0.07%, while the index has advanced 11.54% in the previous three months. Register for your complimentary reports on these five stocks at:
MDCO: 29.79 (+0.91), AUXL: 36.47 (-0.06), SCLN: 7.85 (+0.08), NKTR: 13.54 (-0.14), HSP: 87.35 (unch)
FDA clears Daiichi-Sankyo anticoagulant
Seeking Alpha - at Seeking Alpha - Thu Jan 08, 6:55PM CST
PTLA: 34.96 (+3.13), PFE: 34.64 (-0.23), BMY: 60.04 (+0.56), JNJ: 99.62 (+1.18), ISIS: 63.86 (-0.43), MDCO: 29.79 (+0.91), BAX: 70.39 (+0.31), AZN: 69.96 (+0.20), MRK: 58.81 (-0.07), SCLN: 7.85 (+0.08), MSLI: 1.96 (+0.08)
